RA
JAZZ icon

Royce & Associates’s Jazz Pharmaceuticals JAZZ Stock Holding History

Royce & Associates’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-31,900
Closed -$4.42M – 1437
2014
Q1 		$4.42M Sell
31,900
-108,700
-77% -$16.4M 0.01% 911
2013
Q4 		$17.8M Sell
140,600
-9,700
-6% -$1M 0.05% 452
2013
Q3 		$13.8M Sell
150,300
-33,700
-18% -$2.72M 0.04% 520
2013
Q2 		$12.6M Buy
+184,000
New +$11.2M 0.04% 538

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.62B AUM 39.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Royce & Associates's JAZZ Position: Q2 2014 in Review

Royce & Associates sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2014, closing a stake of 31,900 shares — an estimated $4.42M sold.

Royce & Associates first reported a position in JAZZ in Q2 2013 and held it in 4 quarters. The position peaked at $17.8M in Q4 2013. 305 funds tracked by Wall St. Rank hold JAZZ as of Q2 2014.

  • Royce & Associates reported no remaining Jazz Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Royce & Associates sold 31,900 Jazz Pharmaceuticals shares in Q2 2014, an estimated $4.42M.
  • Royce & Associates first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Royce & Associates's Jazz Pharmaceuticals position peaked at $17.8M in Q4 2013.
  • 305 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2014.

Based on Royce & Associates's 13F filing for Q2 2014, filed 11 Aug 2014.